Literature DB >> 31435021

The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression.

Bin-Jin Hwang1, Yang Zhang2,3, Jaime M Brozowski1,4, Zhen Liu2,5, Susan Burette2, Kendall Lough6, Christof C Smith1, Yue Shan7, Jinbo Chen8, Ning Li2, Scott Williams6, Maureen Su9,10, Paul Googe2, Nancy E Thomas2,10, Zhi Liu11,12,13.   

Abstract

BP180, also termed collagen XVII, is a hemidesmosomal transmembrane glycoprotein expressed in basal keratinocytes, and functions as a cell-matrix adhesion molecule in the dermal-epidermal junction of the skin. Its function, other than cell-matrix adhesion, remains unclear. We generated a mouse strain with BP180 dysfunction (termed ∆NC16A), which develops spontaneous skin inflammation accompanied by an influx of myeloid derived suppressor cells (MDSCs). We used the B16 mouse melanoma model to demonstrate that BP180 dysfunction in either skin or basal keratinocytes promotes MDSC influx into skin and tumor progression. MDSC depletion reduced tumor progression in ∆NC16A mice, demonstrating a critical role for BP180 dysfunction-driven MDSCs in melanoma progression. This study provides the first direct evidence that BP180, a cell-cell matrix adhesion molecule, possesses antitumor function through modulating infiltration of MDSCs. Basal keratinocytes actively participate in skin microenvironment changes caused by BP180 dysfunction. ∆NC16A mice could be a new animal model to study the melanoma microenvironment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31435021      PMCID: PMC6908749          DOI: 10.1038/s41388-019-0961-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  The N terminus of the transmembrane protein BP180 interacts with the N-terminal domain of BP230, thereby mediating keratin cytoskeleton anchorage to the cell surface at the site of the hemidesmosome.

Authors:  S B Hopkinson; J C Jones
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

2.  Analysis of the interactions between BP180, BP230, plectin and the integrin alpha6beta4 important for hemidesmosome assembly.

Authors:  Jan Koster; Dirk Geerts; Bertrand Favre; Luca Borradori; Arnoud Sonnenberg
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

3.  Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180.

Authors:  G J Giudice; D J Emery; L A Diaz
Journal:  J Invest Dermatol       Date:  1992-09       Impact factor: 8.551

4.  Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8.

Authors:  Françoise Van den Bergh; Steven L Eliason; Brian T Burmeister; George J Giudice
Journal:  Exp Dermatol       Date:  2012-08       Impact factor: 3.960

Review 5.  Regulation of hemidesmosome disassembly by growth factor receptors.

Authors:  Coert Margadant; Evelyne Frijns; Kevin Wilhelmsen; Arnoud Sonnenberg
Journal:  Curr Opin Cell Biol       Date:  2008-06-24       Impact factor: 8.382

6.  Transmembrane collagen XVII is a novel component of the glomerular filtration barrier.

Authors:  Tiina Hurskainen; Jyri Moilanen; Raija Sormunen; Claus-Werner Franzke; Raija Soininen; Stefanie Loeffek; Laura Huilaja; Matti Nuutinen; Leena Bruckner-Tuderman; Helena Autio-Harmainen; Kaisa Tasanen
Journal:  Cell Tissue Res       Date:  2012-03-29       Impact factor: 5.249

7.  Humanization of autoantigen.

Authors:  Wataru Nishie; Daisuke Sawamura; Maki Goto; Kei Ito; Akihiko Shibaki; James R McMillan; Kaori Sakai; Hideki Nakamura; Edit Olasz; Kim B Yancey; Masashi Akiyama; Hiroshi Shimizu
Journal:  Nat Med       Date:  2007-02-25       Impact factor: 53.440

8.  Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa.

Authors:  J A McGrath; B Gatalica; A M Christiano; K Li; K Owaribe; J R McMillan; R A Eady; J Uitto
Journal:  Nat Genet       Date:  1995-09       Impact factor: 38.330

9.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Authors:  Zhi Liu; Wen Sui; Minglang Zhao; Zhuowei Li; Ning Li; Randy Thresher; George J Giudice; Janet A Fairley; Cassian Sitaru; Detlef Zillikens; Gang Ning; M Peter Marinkovich; Luis A Diaz
Journal:  J Autoimmun       Date:  2008-10-14       Impact factor: 7.094

Review 10.  Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.

Authors:  Lisa Leighty; Ning Li; Luis A Diaz; Zhi Liu
Journal:  Arch Dermatol Res       Date:  2007-09-19       Impact factor: 3.017

View more
  5 in total

1.  COL17A1 germline variant p.Ser1029Ala and mucosal malignant melanoma: An autopsy study.

Authors:  Daike Tong; Masashi Tanaka; Hidetaka Eguchi; Yasushi Okazaki; Masaaki Muramatsu; Tomio Arai
Journal:  Mol Clin Oncol       Date:  2021-12-14

2.  Non-Cell-Autonomous Activity of the Hemidesmosomal Protein BP180/Collagen XVII in Granulopoiesis in Humanized NC16A Mice.

Authors:  Lin Lin; Bin-Jin Hwang; Ning Li; Paul Googe; Luis A Diaz; Ed Miao; Barbara Vilen; Nancy E Thomas; Jenny Ting; Zhi Liu
Journal:  J Immunol       Date:  2020-09-30       Impact factor: 5.422

Review 3.  Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy.

Authors:  Justyna Mazurkiewicz; Aleksandra Simiczyjew; Ewelina Dratkiewicz; Marcin Ziętek; Rafał Matkowski; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

Review 4.  The Role of Collagen XVII in Cancer: Squamous Cell Carcinoma and Beyond.

Authors:  Virginia A Jones; Payal M Patel; Frederick T Gibson; Adriana Cordova; Kyle T Amber
Journal:  Front Oncol       Date:  2020-03-19       Impact factor: 6.244

5.  Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study.

Authors:  Khalaf Kridin; Jennifer E Hundt; Ralf J Ludwig; Kyle T Amber; Dana Tzur Bitan; Arnon D Cohen
Journal:  Arch Dermatol Res       Date:  2021-03-09       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.